Dose Intensity Analysis of Melphalan and Prednisone in Multiple Myeloma
- 18 May 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 80 (6) , 414-418
- https://doi.org/10.1093/jnci/80.6.414
Abstract
The average relative dose intensity (DI) of conventional oral melphalan and prednisone therapy received by 93 newly diagnosed multiple myeloma patients was correlated with survival and with percent reduction in M-protein. A survival advantage was shown with increasing average relative DI of melphalan and prednisone. Multivariate analysis showed survival to correlate with increasing DI of prednisone (P = .05) but not with the DI of melphalan (P = .93) nor with the percent decrement in M-protein (P = .10). These results suggest that the initial management of myeloma should be reassessed, with particular emphasis on more intensive therapy employing high-dose steroids. [J Natl Cancer Inst 1988; 80: 414–418]Keywords
This publication has 16 references indexed in Scilit:
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Chemotherapy for multiple myelomaCancer, 1984
- COMPARISON OF 2 COMBINATION CHEMOTHERAPY REGIMENS FOR MULTIPLE-MYELOMA - METHYL-CCNU, CYCLOPHOSPHAMIDE, AND PREDNISONE VERSUS MELPHALAN AND PREDNISONE1980
- PRETREATMENT TUMOR MASS, CELL-KINETICS, AND PROGNOSIS IN MULTIPLE-MYELOMA1980
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979
- Clinical Staging in Multiple MyelomaBritish Journal of Haematology, 1979
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Melphalan and MyelomaAnnals of Internal Medicine, 1970
- Melphalan Therapy for Plasma Cell MyelomaBlood, 1968
- THE SURVIVAL TIME OF PATIENTS WITH PLASMOCYTIC MYELOMA1960